Man who died in boating accident off Nantasket Beach is identified. What we know
The 56-year-old was found unresponsive in the water around noon on Saturday after the boat he was in capsized, the Plymouth County district attorney's office said in a news release.
LaRhette was pulled aboard a U.S. Coast Guard vessel and taken to Coast Guard Station Point Allerton, where he was pronounced dead, the DA's statement said. No other people or vessels were missing. The state medical examiner will determine the official cause of death.
At the time of his death, LaRhette was chief business officer at LabCentral, a Cambridge nonprofit that provides shared lab space, equipment and support to biotech startups. He had been in the position for five years, according to his LinkedIn profile.
In an Aug. 11 tribute on the company's blog, LabCentral CEO Johannes Fruehauf called him 'an extraordinary leader whose kindness, compassion, and dedication to innovation in biotech and life sciences shaped LabCentral in immeasurable ways.'
'Beyond his professional contributions, Mike will be remembered for his humanity ‒ the way he listened and cared,' Fruehauf said in the blog. 'To say that he will be missed is the most extraordinary understatement.'
LabCentral said it would share more in the coming weeks about ways to honor and celebrate his life and legacy.
This article originally appeared on The Patriot Ledger: Michael LaRhette, of Hingham, dies after boat capsizes off Nantasket
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
5 hours ago
- Associated Press
Gigatrends, AI, and the Future of Oncology Clinical Pathways to Take Center Stage at HMP Global's CPC+CBEx 2025
Renowned futurist and Delphi Group Chairman & Founder Thomas Koulopoulos to deliver keynote at national event held September 5-6 in Boston. 'The next wave of healthcare won't reward those who build bigger hospitals or prettier dashboards—it will reward those who turn clinical pathways into adaptive, learning ecosystems.'— Thomas Koulopoulos, Delphi Group Founder & Chairman MALVERN, PA, UNITED STATES, August 15, 2025 / / -- Against a backdrop of rapid innovation and mounting complexity in oncology, the 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx) will convene September 5–6 in Boston, Massachusetts. The event will bring together cancer care leaders, payers, and innovators to examine how major trends—artificial intelligence, emerging treatments, stakeholder collaboration, whole-person care, and workforce transformation—are reshaping the design and implementation of clinical pathways and value-based care strategies. Keynote speaker Thomas Koulopoulos will deliver keynote remarks, 'Navigating Tomorrow's Healthcare Gigatrends,' from 9:25 – 10:10 AM on September 5, exploring how healthcare organizations can evolve legacy models into adaptive, AI-supported systems. Koulopoulos is Chairman and Founder of Delphi Group, a 30-year-old Boston think tank named one of the fastest growing private companies by Inc. Magazine, a renowned author and inventor, and the founding partner of Acrovantage Ventures, which invests in early-stage technology startups. What is Clinical Pathways Congress + Cancer Care Business Exchange? The Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx) is a national conference focused on the design, implementation, and evolution of oncology clinical pathways. The event brings together leaders across cancer care, policy, pharmaceutical innovation, and health systems to accelerate value-based care strategies, healthcare infrastructure solutions, and market access innovations that redefine oncology. 2025 Educational Program Highlights • AI-Enabled Pathways: Explore how artificial intelligence, real-time data, and digital tools are transforming pathway design and clinical decision-making in oncology. • Value-Based Oncology Care: Learn how evolving CMS policies and payment models are reframing cancer care economics—and how pathways can serve as strategic levers for value creation. • Collaborative Leadership: Attend panel sessions featuring oncologists, pharmacists, data scientists, health system executives, and policy advocates working to align clinical, operational, and financial priorities. • Real-World Tools for Implementation: Gain access to practical implementation toolkits and strategies showcased through high-impact, peer-reviewed programming—offering actionable insights to support frontline adoption of clinical pathways and drive measurable outcomes. Key Benefits of Attending • Understand how top cancer organizations combat staffing strain and burnout by leveraging AI, expanding roles, and building resilient models. • Join providers, payers, and pathway developers as they collaborate to accelerate pathway adoption and deliver optimal access assistance. • Gain insider perspectives from pathway developers and clinical leaders on how pharma can meaningfully engage to shape inclusion decisions. • Participate in curated B2B networking through the Cancer Care Business Exchange (CBEx). • Earn CME/CE credits while gaining practical, system-wide strategies. Thomas Koulopoulos on Gigatrends and the Future of Oncology • How AI and virtual health can create a continuous care loop: 'AI's pattern-recognition and virtual health's 'anywhere, anytime' reach fuse into a continuous care loop ... The prize: fewer cliff-edge hospitalizations and a seamless hand-off from prevention to acute to chronic management.' • Why clinical pathways are the lever for value over cost: 'When pathways are built around outcomes instead of encounters, they become the financial Rosetta Stone that translates 'spend' into 'health value.'' • The future of care systems: 'The next wave of healthcare won't reward those who build bigger hospitals or prettier dashboards—it will reward those who turn clinical pathways into adaptive, learning ecosystems.' Who Should Attend • Cancer center executives, innovation directors, and service line directors • Oncology operations and quality leaders • Pathway implementation managers and VBC strategists • Health economists, outcomes researchers, and market access teams • Consultants and digital health innovators Event details • Event: Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx) • Dates: September 5–6, 2025 • Location: Boston, Massachusetts • Event Website About HMP Global HMP Global is the omnichannel market leader in healthcare events, education, and insight — with a mission to improve patient care. For 40 years, the company has built trusted brands including Psych Congress, the premier source for mental health education, and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP Global partners with leading experts around the world to deliver more than 450 annual events, medical strategy, and marketing for pharmaceutical and medical device customers through HMP Collective, and pharmaceutical market insight, engaging a global community of healthcare stakeholders that includes nearly 2 million clinicians across 600 medical specialties as well as managed care, behavioral health, senior living, emergency medical, and pharmaceutical commercialization professionals. For more information, follow HMP Global on LinkedIn or visit Sandi Beason, APR HMP Global [email protected] Visit us on social media: LinkedIn Facebook Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
7 hours ago
- Yahoo
Global Digital Pathology Market to Reach $13.7 Billion in 2029
'BCC Research explores how AI-driven workflows, strategic investment, and cross-regional collaboration are shaping the digital pathology market of the future.' Boston, Aug. 15, 2025 (GLOBE NEWSWIRE) -- As global demand for precision diagnostics rises, digital pathology is reshaping how clinical labs, research institutions, and healthcare systems operate. From AI-assisted image analysis to remote pathology consultations, leading players such as Roche, Nikon Instruments, and Indica Labs are advancing innovations that optimize workflows, increase diagnostics speed, and improve collaboration across regions. According to the report, the increasing incidence of cancer, widespread adoption of digital workflows, and rising investments in cloud-based imaging and analytics are reshaping the pathology value chain. The global market is expected to grow from $7.8 billion in 2024 to $13.7 billion by the end of 2029, growing at a CAGR of 11.9% from 2024 to 2029. As North America maintains leadership and Europe expands its clinical and research integration, the Asia-Pacific market is growing rapidly. Vendors must navigate technical integration, cybersecurity, and cost-access barriers to fully capitalize on these opportunities. Market Insights and Strategic Trends Shaping Growth Digital pathology is transitioning from niche adoption to global scaling. Hospitals and diagnostic labs are increasingly investing in AI-enabled image analysis, real-time collaboration tools, and teleconsultation platforms. Clinical utility is expanding beyond cancer diagnosis into chronic disease management, R&D, and education. With healthcare systems under pressure to reduce turnaround time and increase diagnostic accuracy, digital platforms offer a scalable, cost-effective solution to optimize pathology workflows. (Chapter 2: Market Overview; Chapter 3: Market Dynamics) Financial investment in digital pathology continues to rise, driven by venture capital, public health spending, and cross-border collaborations. Funding rounds and strategic alliances are fueling innovation in smart imaging, automated analysis, and cloud-integrated platforms. As laboratories seek cost-effective alternatives to conventional microscopy, companies are rolling out tailored packages that integrate storage, analysis, and compliance tools. (Chapter 3: Market Dynamics; Chapter 6: Emerging Trends and Technologies) Many of the leading companies are pursuing dual-track strategies—expanding both product portfolios and regional presence. For instance, global manufacturers are offering tiered solutions for academic centers and high-throughput hospital labs. At the same time, mergers, acquisitions, and co-development partnerships are being used to penetrate new regions and clinical verticals. These strategies not only accelerate commercialization but also support long-term financial sustainability. (Chapter 9: Competitive Landscape; Chapter 5: Market Segmentation Analysis) Investments are particularly noticeable in image analytics, where AI and machine learning are enabling more precise quantification of biomarkers and improved pattern recognition. Cloud-based platforms are receiving strategic focus, allowing remote access, reduced IT burden, and scalable deployment. Organizations are also adopting outcome-based business models, offering solutions-as-a-service to improve affordability. (Chapter 6: Emerging Trends and Technologies; Chapter 9: Competitive Landscape) Digital pathology vendors are aligning with ESG priorities, embedding sustainability into device development and supply chain strategies. This includes reducing energy consumption, enabling remote workflows that limit physical transport of samples, and improving data transparency in diagnostic reporting. These commitments are becoming important differentiators in procurement processes. (Chapter 7: ESG Developments) Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $7.0 billion Market size forecast $13.7 billion Growth rate CAGR of 11.9% for the forecast period of 2024-2029 Segments covered System, Type, Application, End User, and Region Regions covered North America, Asia-Pacific, Europe, Rest of the World Countries covered U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, China, South Korea, Australia, South America, and Middle East and Africa Market drivers Cost-effectiveness driving expansion. Growing adoption of digital pathology to enhance lab efficiency. Increasing incidence of cancer. Increasing investments and funding in digital pathology. Additional Insights: Paige's AI Breakthrough: In January 2024, Paige launched Virchow, a groundbreaking solution built on its Pathology Foundation Model. Developed using Microsoft's computational infrastructure, Virchow is capable of detecting cancer across 17 tissue types—including skin, lung, gastrointestinal, and rare tumor variants. Prov-GigaPath Sets New Standards: The AI-powered Prov-GigaPath model represents a major advances in digital pathology. Leveraging vision transformer architecture and real-world datasets, it enables enhanced mutation prediction, cancer subtyping, and vision-language tasks, tackling challenges such as data scarcity and slide complexity. Market leaders include: 3DHistech Ltd. Apollo Enterprise Imaging Corp. Clinisys Inc. Corista F. Hoffmann-La Roche Ltd. Fujifilm Holdings Corp. Huron Technologies International Inc. Indica Labs LLC. Koninklijke Philips N.V. Leica Biosystems Nussloch GmbH Ligolab Information Systems Mikroscan Technologies Inc. Nikon Instruments Inc. Visiopharm A/S Xifin Inc. Get your copy of the report directly from BCC Research. To request more information or complete your purchase, connect with us at info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
8 hours ago
- Bloomberg
Boston Mayor Accuses ICE of Keeping Secret Who They're Arresting
Boston Mayor Michelle Wu has vowed to find out from US Immigration and Customs Enforcement who they're arresting in her city and why. But despite repeated efforts to get answers, federal immigration authorities have refused to provide even basic details, Wu told Bloomberg. Wu pledged in June to regularly submit Freedom of Information Act requests to ICE, seeking the names of immigrants who have been ensnared in deportation efforts in Boston; an explanation of why they were detained, including criminal records; and the location where they are being held. Communication on those requests has been paltry, with federal officials failing to share any information, Wu said.
